Rationale and design of the MASS COMM trial: A randomized trial to compare percutaneous coronary intervention between MASSachusetts hospitals with cardiac surgery on-site and COMMunity hospitals without cardiac surgery on-site - 16/11/11
, Sharon-Lise T. Normand, PhD b, c, Michael Pencina, PhD d, Donald E. Cutlip, MD b, e, Cathy Jeon, MD, MSc f, Paul Dreyer, PhD g, Richard E. Kuntz, MD, MSc h, Donald S. Baim, MD i, k, Alice K. Jacobs, MD jRésumé |
Background |
Emergency surgery has become an increasingly rare event after percutaneous coronary intervention (PCI). There have been no randomized trials evaluating whether cardiac surgery services on-site are essential for patient safety and optimal outcomes during and after PCI.
Study Design |
The MASS COMM trial (ClinicalTrials.gov no. NCT01116882) is a randomized trial comparing the safety and effectiveness of nonemergency PCI at hospitals without surgery on-site (SOS) (non-SOS hospitals) and hospitals with SOS (SOS hospitals). A total of 3,690 subjects will be randomized in a 3:1 fashion to undergo PCI at non-SOS and SOS hospitals, with follow-up at hospital discharge, 30 days, and 12 months after PCI. The rate of major adverse cardiac events (all-cause mortality, myocardial infarction, repeat revascularization, and stroke) will serve as the primary safety end point at 30 days and the primary effectiveness end point at 12 months. The design is a 1-way randomized trial with a statistical hypothesis of noninferiority of nonemergency PCI at non-SOS hospitals for both safety and effectiveness end points.
Conclusions |
This multicenter, randomized trial will compare the relative safety and effectiveness of nonemergency PCI at sites with and without cardiac SOS.
Le texte complet de cet article est disponible en PDF.Plan
| For both Drs Baim and Kuntz, their participation in the trial design occurred when they were employed at the Brigham and Women's Hospital and Harvard Medical School in Boston. RCT reg number NCT01116882. |
Vol 162 - N° 5
P. 826-831 - novembre 2011 Retour au numéro
Article précédent
- The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study
- Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald, Ph. Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Deborah L. Price, Roland Chen, Jacob Udell, Itamar Raz
- The first call from Dad
- Maurice R. “Pat” Berdan, Lisa G. Berdan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?